Physician profile
Jonathan G Wash
NPI 1003899972
$2,914.69
in general payments reported to CMS, 2019-2025
12 companies · $320 in 2025
The $320 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2021: $378 · 2022: $303 · 2023: $283 · 2024: $459 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975 · Long Term Medical Supply Or Device Loan: $87.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.24 |
| Long Term Medical Supply Or Device Loan | $87.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pylant Medical | $1,412.59 | 2019-2023 | |
| Alafair Biosciences, INC. | $263.00 | 2022-2025 | Versawrap |
| Orthofix Medical, INC. | $189.78 | 2019-2021 | |
| Sanara Medtech INC. | $175.84 | 2024 | Celleraterx |
| Stryker Corporation | $172.54 | 2024 | Anchorage, Ortholoc 2 Lapifuse, Actishield |
| Averitas Pharma INC. | $169.44 | 2025 | Qutenza |
| Integra Lifesciences Corporation | $131.54 | 2023-2024 | Integra, Acell, Integra Dermal Regeneration Template |
| Next Science LLC | $130.36 | 2021 | |
| Depuy Synthes Sales INC. | $117.94 | 2022 | |
| Smith+Nephew, INC. | $72.90 | 2025 | Salto Talaris Total Ankle Prosthesis, Cadence, Panta 2 |
| Crossroads Extremity Systems, LLC | $60.16 | 2021 | |
| Kci USA, INC. | $18.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.